Acute Leukemia Clinical Trial
Official title:
Development of a Method for Assessing the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies Using Flow Cytometry
The purpose of this study is to develop a highly sensitive method for assessing the functional activity of platelets for use in the differential diagnosis of thrombocytopenia and platelet defects.
Status | Not yet recruiting |
Enrollment | 200 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 1 Year to 17 Years |
Eligibility | Inclusion Criteria: - Pediatric participants with hemorrhagic syndrome (hemorrhagic rash, bruising, bleeding, increased bleeding of the skin and mucous membranes, spontaneous hemorrhages in soft tissues and joints) - Pediatric participants with acute leukemia - Parameters of the plasma level of blood coagulation correspond to the age normal levels Exclusion Criteria: - Anticoagulation drug therapy - Antiaggregation drug therapy - Biologically active additives |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Expression of CD42b by platelets | Assessment of platelet functional activity by the detection of CD42b | baseline | |
Primary | Expression of CD41 by platelets | Assessment of platelet functional activity by the detection of CD41 | baseline | |
Primary | Expression of PAC-1 by platelets | Assessment of platelet functional activity by the detection of PAC-1 | baseline | |
Primary | Expression of CD63 by platelets | Assessment of platelet functional activity by the detection of CD63 | baseline | |
Primary | Expression of CD62p by platelets | Assessment of platelet functional activity by the detection of CD62p | baseline | |
Primary | Expression of Annexin V by platelets | Assessment of platelet functional activity by the detection of Annexin V | baseline | |
Primary | Level of platelet aggregation | Assessment of platelet functional activity by turbidimetric aggregometry | baseline | |
Primary | Impedance of platelet aggregates | Assessment of platelet functional activity by impedance aggregometry | baseline | |
Primary | Fibrinogen level | Assessment of blood coagulation using Fibrinogen level test | baseline | |
Primary | Prothrombin test | Assessment of blood coagulation using Prothrombin test | baseline | |
Primary | Thrombin time | Assessment of blood coagulation using Thrombin time test | baseline | |
Primary | aPTT | Assessment of blood coagulation using aPTT | baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05088356 -
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
|
Phase 1 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT02356159 -
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05170828 -
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
|
Phase 1 | |
Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
Active, not recruiting |
NCT01956630 -
Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT
|
Phase 1/Phase 2 | |
Completed |
NCT00988013 -
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
|
N/A | |
Enrolling by invitation |
NCT01728402 -
Pathogenesis of Hematologic Malignancies
|
||
Active, not recruiting |
NCT03595800 -
Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen
|
Phase 3 | |
Completed |
NCT02440178 -
Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia
|
Phase 2 | |
Recruiting |
NCT05071482 -
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
|
Phase 4 | |
Completed |
NCT03042676 -
Electronic Database for the Follow up of the ATG_FamilyStudy
|
||
Withdrawn |
NCT03138395 -
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
|
N/A | |
Completed |
NCT04597086 -
Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients
|
N/A | |
Terminated |
NCT03588936 -
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
|
Phase 1 | |
Recruiting |
NCT05521204 -
Olverembatinib for FGFR1-rearranged Neoplasms
|
Phase 2 | |
Not yet recruiting |
NCT04084327 -
Immunophenotyping of Acute b Cell Lymphoblstic Leukemia
|
||
Terminated |
NCT00852709 -
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
|
Phase 1 | |
Not yet recruiting |
NCT06026839 -
Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
|